AbbVie beats expectations, despite slowing US Humira sales

29 January 2016

US drugmaker AbbVie (NYSE: ABBV) saw its share fall 4.3% to $53.45, after it announced financial results for the fourth quarter and full year 2015,even though these were slightly better than expected.

Worldwide adjusted net revenues were $6.36 billion in the fourth-quarter, up 18.4%. Adjusted diluted earnings per share, excluding intangible asset amortization expense and other specified items, were $1.13 in the fourth quarter, up 27%, and just ahead of analysts’ consensus forecasts of $1.12 on revenues of $6.39 billion. Diluted earnings per share were $0.92 on a generally-accepted accounting principles (GAAP) basis.

For the full-year 2015, AbbVie posted net revenues of $22.82 billion, a rise of 22.1%. Adjusted earnings per share were $4.29, an increase of29.2%. GAAP EPS came in at $3.13.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK